{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T05:34:19Z","timestamp":1736919259135,"version":"3.33.0"},"reference-count":21,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1055\/a-2255-6329","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:19:21Z","timestamp":1736900361000},"page":"83-90","source":"Crossref","is-referenced-by-count":0,"title":["Behandlung der chronischen Nierenkrankheit bei IgA-Nephropathie"],"prefix":"10.1055","volume":"150","author":[{"given":"Severin","family":"Schricker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Schanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Latus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns","volume":"105","author":"A Levin","year":"2024","journal-title":"Kidney Int"},{"issue":"03","key":"ref2","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA Nephropathy: Core Curriculum 2021","volume":"78","author":"P Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"06","key":"ref3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-Term Outcomes in IgA Nephropathy","volume":"18","author":"D Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"ref4","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1093\/ndt\/gfx236","article-title":"The longer the better: follow-up in seemingly \u2018benign\u2019 immunoglobulin a nephropathy","volume":"32","author":"U Kunter","year":"2017","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"ref5","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1093\/ndt\/gfad146","article-title":"IgA nephropathy in adults-treatment standard","volume":"38","author":"PJ Gleeson","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"01","key":"ref6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1681\/ASN.0000000000000242","article-title":"Treatment of IgA Nephropathy: A Rapidly Evolving Field","volume":"35","author":"K El Karoui","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"03","key":"ref7","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy","volume":"14","author":"A Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"06","key":"ref8","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1159\/000525001","article-title":"Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis","volume":"146","author":"R Ebbestad","year":"2022","journal-title":"Nephron"},{"issue":"04","key":"ref9","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"BH Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1056\/NEJMoa2204233","article-title":"Impact of Diabetes on The Effects Of Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"BH Rovin","year":"2023","journal-title":"Lancet"},{"issue":"06","key":"ref13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"R Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"05","key":"ref14","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-024-02036-1","article-title":"Drugs in Development to Treat IgA Nephropathy","volume":"84","author":"L Del Vecchio","year":"2024","journal-title":"Drugs"},{"issue":"23","key":"ref15","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"Intensive Supportive Care plus Immunosuppression in IgA Nephropathy","volume":"373","author":"T Rauen","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"ref16","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial","volume":"327","author":"J Lv","year":"2022","journal-title":"JAMA"},{"issue":"S 02","key":"ref17","doi-asserted-by":"publisher","first-page":"ii1","DOI":"10.1093\/ckj\/sfad199","article-title":"Ethnicity and IgA nephropathy: worldwide differences in epidemiology, timing of diagnosis, clinical manifestations, management and prognosis","volume":"16","author":"M Lee","year":"2023","journal-title":"Clin Kidney J"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"R Lafayette","year":"2023","journal-title":"Lancet"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"S506","DOI":"10.1016\/j.ekir.2024.02.1414","article-title":"WCN24\u20131506 Efficacy and Safety of Iptacopan in Patients with IgA Nephropathy: Interim Results from the Phase 3 APPLAUSE-IgAN Study","volume":"9","author":"V Perkovic","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"08","key":"ref20","doi-asserted-by":"publisher","first-page":"sfae230","DOI":"10.1093\/ckj\/sfae230","article-title":"Long-term outcomes of patients with IgA nephropathy in the German CKD cohort","volume":"17","author":"E Stamellou","year":"2024","journal-title":"Clin Kidney J"},{"issue":"09","key":"ref22","doi-asserted-by":"publisher","first-page":"sfae237","DOI":"10.1093\/ckj\/sfae237","article-title":"Sodium glucose co-transporter 2 inhibitors in the treatment of glomerular diseases: a CKJ controversy","volume":"17","author":"F Caravaca-Font\u00e1n","year":"2024","journal-title":"Clinical Kidney Journal"},{"issue":"02","key":"ref23","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ndt\/gfad175","article-title":"Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis","volume":"39","author":"F Caravaca-Font\u00e1n","year":"2024","journal-title":"Nephrol Dial Transplant"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2255-6329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:19:38Z","timestamp":1736900378000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2255-6329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,1,14]]},"published-print":{"date-parts":[[2025,1]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2255-6329","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}